In April of 2022, the FDA issued its 9th guidance to combat the negative impacts of demographically-biased trials. But how can the industry ensure that this guidance achieves the results that all involved want and need? What can stakeholders do that has not already been done for more fully enrolled – and equitable – clinical trials?
To answer that question, Syneos Health experts break down how marketers must pay attention to the stakeholders at the core of every clinical trial: patients and caregivers and their existing relationships with healthcare providers.
Download the article below
